Atlas Trials

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

Clinical trial NCT00568945 · COMPLETED

Trial details

NCT number
NCT00568945
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Atrial Fibrillation
Start date
2008-01-01
Primary completion
2008-11-01
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.